Enjoy complimentary customisation on priority with our Enterprise License!
The Sepsis Therapeutics Market is estimated to grow by USD 1.42 billion, at a CAGR of 6.98% between 2023 and 2028. The global rise in the geriatric population has contributed to an increasing incidence of sepsis, underscoring the importance of advancements in healthcare infrastructure. As healthcare systems evolve, there is a growing emphasis on improving the management and treatment of sepsis through enhanced infrastructure and medical interventions. This demographic shift highlights the need for proactive measures to address the complex healthcare needs of elderly individuals, including effective sepsis detection and management. By investing in healthcare infrastructure and implementing preventive strategies, healthcare providers can better respond to the challenges posed by the rising incidence of sepsis among the aging population.
To learn more about this report, Request Free Sample
The hospitals segment is estimated to witness significant growth during the forecast period. The hospitals segment stands as the frontline institutions in the global market, representing critical hubs for the diagnosis, treatment, and management of sepsis cases. In addition, exemplary institutions like the Mayo Clinic, renowned for its patient-centered approach and innovative medical practices, showcase the comprehensive care provided to sepsis patients. Furthermore, the Cleveland Clinic, with its commitment to research-driven solutions and early intervention strategies, contributes significantly to improved sepsis outcomes.
Get a glance at the market contribution of various segments Download PDF Sample
The hospitals segment was the largest segment and was valued at USD 1.39 billion in 2018. Moreover, in hospitals, sepsis-therapeutics are administered across various departments, including emergency rooms, intensive care units (ICUs), and surgical wards, reflecting the urgency and complexity of sepsis-cases. In addition, these institutions prioritize protocols for prompt identification, aggressive treatment, and continuous monitoring, underscoring the crucial role hospitals play in combating sepsis. Furthermore, factors such as the ongoing advancements in hospital infrastructure, technological integration for swift diagnosis and treatment, and concerted efforts to enhance sepsis awareness and management practices within these healthcare institutions globally are fueling the growth of this segment, which in turn drives the market growth during the forecast period.
The antimicrobial therapy segment is an essential aspect of Septicemia Therapy, comprising the use of medications to combat the underlying infectious agents. In addition, antibiotics play a central role in addressing bacterial infections associated with sepsis. Moreover, these drugs are administered through various routes, including intravenous, to ensure rapid and effective distribution throughout the body. In addition, timely initiation of antimicrobial therapy is pivotal, as it directly impacts the success of Septic Shock Intervention by halting the progression of the infection. Furthermore, advancements in precision medicine and a better understanding of microbial genomics are expected to fuel the evolution of antimicrobial therapy, ensuring its efficacy and relevance in the dynamic landscape of sepsis-treatment, which in turn drives the market growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is projected to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have extensively outlined the regional trends and drivers that will influence the market during this time. North America holds a pivotal role in the global sepsis treatment market, with the US and Canada emerging as major revenue contributors. The region boasts a highly advanced healthcare infrastructure, state-of-the-art medical research, and a robust regulatory framework. Institutions like the Mayo Clinic and Johns Hopkins Hospital in the US significantly contribute to advancements in sepsis diagnosis and treatment. Moreover, the region's high awareness among healthcare professionals and the public fuels the demand for effective therapeutics, thereby driving market growth in North America during the forecast.
The market is witnessing significant growth, driven by the pressing need to address the high mortality rate associated with this critical condition. Matinas BioPharma, in collaboration with Government funding from the Canadian Institutes, is pioneering research into novel treatments targeting both bacterial and viral causes of sepsis. Clinical trials focusing on oral aminoglycoside and cephalosporins like Ceftobiprole medocaril are showing promising results in ICU patients. Sepsis Canada plays a crucial role in advancing frontiers in sepsis management. Companies like Sandoz offer vital medications such as Zinnat and Zinacef to combat sepsis. Furthermore, advancements in diagnostic tests are enhancing early detection, essential in reducing sepsis-related mortality. With the rising prevalence of diseases like pneumonia, influenza, urinary tract infection, and other bacterial and viral infection, the market is poised for continued growth, supported by strategic financing initiatives.
A significant market growth trend is the rising emphasis on precision medicine in treating infectious diseases like sepsis. This approach tailors therapies based on individual patient characteristics, including genetic, molecular, and immunological factors. It aims to move beyond the conventional approach, optimizing interventions for better outcomes.
For instance, identifying genetic variations can guide targeted therapies, and precision medicine helps determine the most effective antimicrobial agents. As a result, such factors contribute to market growth analysis in the forecast period, shaping strategies in the pharmaceutical industry and driving advancements in adjunctive therapies like immunotherapy and vasopressors for early sepsis detection.
The escalating challenge of antimicrobial resistance (AMR) poses a significant obstacle to market growth. AMR arises when microorganisms like bacteria, viruses, fungi, and parasites evolve to resist drugs intended to eradicate them. This resistance undermines the efficacy of antibiotics, crucial in treating bacterial infections. Excessive use and misuse of antibiotics in healthcare and agriculture expedite the emergence of resistant strains, amplifying the threat to public health.
Additionally, the limited availability of effective antibiotics restricts treatment options for sepsis patients, further impeding market growth drivers in the forecast period for pharmaceutical companies and providers of intravenous fluids.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Adrenomed AG: The company offers sepsis therapeutics solutions such as Adrecizumab.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Global Market Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
You may also be interested in below market reports:
The market is witnessing a surge in activity, driven by the pressing need to address the high mortality rate associated with this critical condition, particularly in Southeast Asia. Pharmaceutical giants like GSK and Fortum are intensifying their company activities and clinical trial activities to develop effective treatments for both bacterial infection and viral infection sepsis. Diagnostic test are becoming increasingly crucial in early detection, particularly among the elderly population susceptible to self-reported morbidity such as diabetes mellitus, heart illness, lower-back symptoms, and asthma. Leveraging medical records and medical knowledge, healthcare providers are optimizing healthcare utilization to manage type 2 diabetes, hypertension, malignancies, and other underlying conditions that predispose individuals to sepsis. With a focus on reducing hospitalizations and fatality rate, the market is witnessing a shift towards targeted therapeutic medications like Xigris, especially for the geriatric population.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
157 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.98% |
|
Market Growth 2024-2028 |
USD 1.42 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
6.78 |
|
Regional analysis |
North America, Europe, APAC, South America, and Middle East and Africa |
|
Performing market contribution |
North America at 35% |
|
Key countries |
US, China, Japan, Germany, and UK |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Adrenomed AG, AM Pharma BV, Astellas Pharma Inc., AstraZeneca Plc, bioMerieux SA, CytoSorbents Corp., F. Hoffmann La Roche Ltd., Hikma Pharmaceuticals Plc, Inotrem S.A., Novartis AG, Pfizer Inc., Sanofi SA, Spectral Medical Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
|
Market dynamics |
Parent market growth analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the market forecast period. |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.